Psychedelics Are Driving a Mental Health Revolution with Long-Lasting Therapeutic Potential

At the BIO International Convention 2025, the forum titled “Psychedelics Are Going Mainstream. Are You Ready for It?” brought together a diverse panel of experts to discuss the future of psychedelic therapies and their integration into mainstream medicine. Moderated by NPR’s Tech Nation host Moira Gunn, the panel featured speakers including MindMed’s Dr. Daniel Karlin, Harvard’s Dr. Sharmin Ghaznavi, Blue Cross Blue Shield’s Dr. Michael Kobernick, EMA’s Dr. Steffen Thirstrup, and patient advocate Katie Walker to explore how psychedelic therapies are set to reshape the treatment landscape for mental health disorders.

Healthcare Systems Prepare for Psychedelic Therapy Integration Amid Advancing Phase 3 trials and Evolving Psychiatric Treatments

At the forum, experts discussed the readiness of healthcare systems to integrate psychedelic therapies. Topics ranged from equitable access and reimbursement frameworks to infrastructure needs and clinical workforce training, showcasing growing interest in how these emerging treatments could fit into existing models of care.

In 2025, the fields of psychiatry and neuroscience in both the United States and Europe are undergoing a notable shift. Led by MindMed, three Phase 3 clinical trials are currently evaluating MM120, a pharmaceutically optimized formulation of LSD (Lysergic acid diethylamide), for its potential in treating Major Depressive Disorder (MDD) and Generalized Anxiety Disorder (GAD). According to MindMed’s Chief Medical Officer Dr. Daniel Karlin, the company’s Phase 2 study of MM120 showed a 50% remission rate after a single dose, with effects lasting up to 12 weeks.

These trials aim to determine whether the psychedelic experience itself contributes to the therapeutic effect. MM120 is administered as an oral disintegrating tablet to ensure consistent delivery and rapid absorption. Notably, the studies are designed without concurrent psychotherapy, focusing on the compound’s efficacy as a stand-alone intervention. This approach may simplify regulatory pathways and support future coverage decisions by payers.

Additionally, Dr. Karlin addressed common misconceptions about MM120’s formulation. “The experience of taking 100 micrograms of MM120 is the experience of taking 100 micrograms of LSD,” he explained, emphasizing that the optimization is centered on pharmacokinetics rather than altering the drug’s psychoactive profile. He also noted that there is no clear clinical evidence supporting the removal of hallucinogenic effects from classic psychedelics. “I’ve become increasingly convinced that the experience of taking the drug is a critical part of the mechanism of action when it comes to treating neurotic disorders.” 

Psychedelic Research Paused Mid-20th Century Resumes Amid Complex and Fragmented European Regulatory Landscape

Psychedelics are far from new. Researchers extensively studied psychedelics from the 1940s through the 1960s, but political and cultural backlash abruptly halted their scientific exploration. Today, regulatory bodies such as the European Medicines Agency (EMA) are cautiously re-engaging with these compounds. Dr. Steffen Thirstrup, EMA’s Chief Medical Officer, noted that over a dozen psychedelic trials are currently underway across Europe for treatment-resistant depression, PTSD, and anxiety disorders.

However, Thirstrup emphasized the complexity of drug development in Europe, where clinical trials and drug approvals remain under the jurisdiction of individual member states despite the EMA’s coordinating role. “Europe is not the United States of Europe,” he said. “Clinical trial authorization is still handled nationally, with each country making its own decision through ethics committees, even when EMA provides scientific advice.” This fragmented structure adds a layer of difficulty, particularly when working with Schedule I substances like psychedelics, which face variable legal and cultural reception across the region.

Further complicating the European regulatory landscape is the absence of harmonized international guidelines for psychedelic studies. Unlike the U.S. Food and Drug Administration (FDA), which has issued specific guidance for psychedelic research, the EMA has instead chosen to incorporate language into broader guidelines for major depressive disorder. As Dr. Thirstrup explained, “We decided to embed psychedelic considerations into existing regulatory frameworks rather than create standalone guidance, but I can foresee that evolving in the future.” He explained that vast differences in diagnosing and treating psychiatric conditions across regions make reaching global consensus on clinical guidelines unlikely in the near term.

FDA Approval Drives Insurance Coverage Amid Access and Cost Challenges for Psychedelic Therapies

With mounting clinical evidence, the next challenge lies in ensuring access and economic viability. Dr. Michael Kobernick, Medical Director at Blue Cross Blue Shield of Michigan, believes insurance reimbursement will depend primarily on FDA approval rather than diagnosis. He pointed to Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a relevant example. “Once it’s approved, it’ll be covered,” he said, noting that prior authorization, such as proof of failed treatment with two antidepressants, may still apply, as is typical with new therapies.

Kobernick expressed concern not just about coverage, but also about access. He emphasized that availability of mental health specialists remains a barrier, especially in underserved communities. In his view, approval alone won’t solve the broader issue of equitable access to care. He also highlighted the importance of health economics and outcomes research, or HEOR, in shaping policy. “We’re clearly going to define a better outcome,” he said, arguing that the cost of these medications is likely to remain reasonable compared to their potential impact. Kobernick sees value in the relationship between cost and meaningful improvement, and he believes psychedelics can deliver both effectively.

Single-Dose LSD Microdosing in MindMed Trial Shows Lasting Impact for Generalized Anxiety Disorder Participants

Katie Walker, a Licensed Certified Social Worker, trauma specialist, and Founder of Grow and Guide Kids, offered a rare dual perspective, as both a mental health clinician and a participant in a psychedelic clinical trial. She recounted her decision to join the MindMed study on LSD microdosing for generalized anxiety disorder as an act of desperation after years of managing anxiety with every available tool: weekly therapy, daily yoga, meditation, and somatic work. Despite her training and efforts, she described the results as minimal. “I was quite literally doing everything just to manage,” she said. When she learned about the trial from a psychiatrist colleague at a social gathering, she immediately volunteered. “I said, ‘I want to be your first,’” Walker recalled.

Walker described the treatment day itself as transformative. “I received just one dose, and the session lasted about 12 hours,” she said. But the impact extended well beyond that timeframe. What stood out most, she noted, was how both the clinical team and her personal therapist approached her with compassion rather than expectations, an approach she believes was critical in allowing her to open up and process the experience authentically. “They met me with curiosity, not prescriptions for how I should feel,” she said.

 Now, as a clinician who has referred patients to similar studies, Walker emphasized that providers must meet patients where they are. “This isn’t about being the best trial participant or getting it right. It’s about supporting people through whatever comes up.” She encouraged mental health professionals to maintain that same sense of openness and flexibility. “The process ended up being way more spiritual than I thought it would,” she said. “No one prepared me for that and I think that’s what made it so powerful.”

Author

Denisse Sandoval